Levitra Effective in Men with ED, Cardiovascular Problems

FEBRUARY 01, 2007
Susan Farley

A recent trial determined that using vardenafil HCl (Levitra) to treat erectile dysfunction (ED) in men with cardiovascular-related conditions showed the first dose to be more effective than placebo. The cardiovascular conditions reviewed included high blood pressure, high cholesterol, and/or diabetes. The randomized, placebo-controlled study of 600 patients with ED used a single, openlabel, 10-mg dose of vardenafil. After completing the sexual encounter profile (SEP), success was determined by penetration (SEP-2) and erection maintenance until completion of intercourse (SEP-3). In the 1-week period, 87% of patients using vardenafil were successful with SEP-2, and 74% were successful with SEP-3. SEP-2 success was achieved in 84% of men with high blood pressure, 84% of men with high cholesterol, and 75% of men with diabetes. Participants who achieved SEP-2 success were randomized to receive vardenafil or placebo for an additional 12 weeks. At the end of that portion of the study, those taking the 10-mg vardenafil had an SEP-2 success rate of 83%, compared with 56% for those taking placebo. Results were published in the November 2006 issue of the International Journal of Clinical Practice.

Ms. Farley is a freelance medical writer based in Wakefield, RI.


The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.



Conference Coverage
News from the year's biggest meetings

Pharmacist Education
Clinical features with downloadable PDFs


Personalize the information you receive by selecting targeted content and special offers.